Ellen M. Brady

Wexford Capital LP (Wexford) is an independent, SEC-registered investment advisor headquartered in West Palm Beach, Florida with additional office in Stamford, Connecticut. The firm was founded by Charles Davidson, Joseph Jacobs and Robert Holtz in 1994. Wexford provides investment advice to a variety of private pooled investment vehicles over which the firm has discretionary trading authority.

Centegen, Inc. develops novel therapeutics to fight serious drug resistant bacterial infections. The company was founded by Dr. Joel B. Braunstein and is headquartered in Pikesville, MD.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Bowdoin College is an independent, nonsectarian, coeducational residential, undergraduate liberal arts institution founded in 1794. It is located in Brunswick, ME.

Northwestern University is a private institution founded in 1851 to serve the Northwest Territory, an area that now includes the states of Ohio, Indiana, Illinois, Michigan, Wisconsin and parts of Minnesota. Northwestern has three campuses

National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD.

The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC.

LifeTech Development Partners LP (LifeTech Development) is a venture capital subsidiary of LifeTech Research, Inc. founded in 2008 by Joel Braunstein. The firm is headquartered in Baltimore, Maryland.

Sphera Funds Management Ltd. (US) (Sphera US) is the New York-based hedge fund management division of Sphera Funds Management Ltd., which is owned by S.R Accord Ltd. (TLV: SRAC), a company headquartered in Israel. Sphera US manages distinct long/short equity strategies. The firm has a diverse investor base that includes pensions, insurance companies, financial institutions and family offices.

C2N Diagnostics LLC is a private company that focuses on mechanism-based approaches to prevent or stop the progression of human neurological disorders. The company is based in St. Louis, MO. The company's lead commercial product, PrecivityAD™, is a mass spectrometry-based test that measures in blood multiple analytes including a?42, a?40, and apolipoprotein e isoforms. This test predicts brain amyloid plaques as determined by PET scan results and received a breakthrough device designation from the Food and Drug Administration in early 2019. C2N Diagnostics aims to bring accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring in the field of neurodegeneration and Alzheimer's disease. The company was founded by Ravi Kiron, Joel Bennett Braunstein, Ilana Fogelman. Joel Bennett Braunstein has been the CEO since incorporation.

Part of Global Genes, Rare-X is a patient advocacy organization based in Washington. Rare-X is focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Rare-X is building the largest collaborative patient-driven, open-data access project for rare diseases ly, gathering structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data sharing technology. Rare-X's goal is to build the largest collaborative patient-driven, open-data access project for rare diseases ly. The American company was founded in 2019 by Nicole Boice. The CEO is Charlene Son Rigby. Rare-X was acquired by Global Genes on February 07, 2023.